Evaluation of osteoclastogenesis via NFκB decoy/mannosylated cationic liposome-mediated inhibition of Pro-inflammatory cytokine production from primary cultured macrophages

Pharmaceutical Research

Volumn 28, Issue 4, 2011, Pages 742-751

  Dinh, Thuy Duong ^a   Higuchi, Yuriko ^a   Kawakami, Shigeru ^a   Yamashita, Fumiyoshi ^a   Hashida, Mitsuru ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

man liposomes; NF B decoy; osteoclastogenesis; proinflammatory cytokines

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LIPOSOME; MANNOSE RECEPTOR; MANNOSYLATED CATIONIC LIPOSOME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME INHIBITION; FEMALE; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZETA POTENTIAL;

ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CATIONS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CYTOKINES; DRUG CARRIERS; FEMALE; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; LIPOSOMES; MACROPHAGES, PERITONEAL; MANNOSE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; OLIGODEOXYRIBONUCLEOTIDES; OSTEOCLASTS; PARTICLE SIZE;

EID: 79955629326     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0366-0     Document Type: Article

References (35)

1. G Schett KG Saag JW Bijlsma 2010 From bone biology to clinical outcome: state of the art and future perspectives Ann Rheum Dis 69 1415 1419 20650876 10.1136/ard.2010.135061 1:CAS:528:DC%2BC3cXhtVykt7fP
2. DV Novack SL Teitelbaum 2008 The osteoclast: friend or foe? Annu Rev Pathol 3 457 484 18039135 10.1146/annurev.pathmechdis.3.121806.151431 1:CAS:528:DC%2BD1cXjsFersLY%3D (Pubitemid 351488289)
3. SL Teitelbaum 2006 Osteoclasts; culprits in inflammatory osteolysis Arthritis Res Ther 8 201 16356195 10.1186/ar1857 (Pubitemid 43264489)
4. BF Boyce L Xing 2008 Functions of RANKL/RANK/OPG in bone modeling and remodeling Arch Biochem Biophys 473 139 146 18395508 10.1016/j.abb.2008.03.018 1:CAS:528:DC%2BD1cXlsFOgt7c%3D
5. G Eghbali-Fatourechi S Khosla A Sanyal WJ Boyle DL Lacey BL Riggs 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J Clin Invest 111 1221 1230 12697741 1:CAS:528: DC%2BD3sXjtFCrs7g%3D (Pubitemid 36519939)
6. N Charatcharoenwitthaya S Khosla EJ Atkinson LK McCready BL Riggs 2007 ct of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women J Bone Miner Res 22 724 729 17295604 10.1359/jbmr.070207 1:CAS:528:DC%2BD2sXpt1yrt7c%3D (Pubitemid 351339101)
7. Y Abu-Amer J Erdmann L Alexopoulou G Kollias FP Ross SL Teitelbaum 2000 Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis J Biol Chem 275 27307 27310 10874036 1:CAS:528: DC%2BD3cXmsVWqtr8%3D
8. J Keffer L Probert H Cazlaris S Georgopoulos E Kaslaris D Kioussis G Kollias 1991 Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis EMBO J 10 4025 4031 1721867 1:CAS:528:DyaK38XhtVCiurw%3D (Pubitemid 21905432)
9. PC Taylor M Feldmann 2009 Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis Nat Rev Rheumatol 5 578 582 19798034 10.1038/nrrheum.2009.181 1:CAS:528:DC%2BD1MXht1WitrnP
10. J Harris J Keane 2010 How tumour necrosis factor blockers interfere with tuberculosis immunity Clin Exp Immunol 161 1 9 20491796 1:CAS:528: DC%2BC3cXps1entb0%3D
11. HL Pahl 1999 Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 18 6853 6866 10602461 10.1038/sj.onc.1203239 1:CAS:528:DyaK1MXotVyhtL0%3D
12. TS Blackwell JW Christman 1997 The role of nuclear factor-kappa B in cytokine gene regulation Am J Respir Cell Mol Biol 17 3 9 9224203 1:CAS:528:DyaK2sXksF2ktL8%3D (Pubitemid 127500814)
13. E Jimi S Ghosh 2005 Role of nuclear factor-kappaB in the immune system and bone Immunol Rev 208 80 87 16313342 10.1111/j.0105-2896.2005.00329.x 1:CAS:528:DC%2BD28Xks1eisA%3D%3D (Pubitemid 41746386)
14. R Morishita T Sugimoto M Aoki I Kida N Tomita A Moriguchi K Maeda Y Sawa Y Kaneda J Higaki T Ogihara 1997 In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction Nat Med 3 894 899 9256281 10.1038/nm0897-894 1:CAS:528: DyaK2sXltVOhs7g%3D (Pubitemid 27353450)
15. S Akhtar S Agrawal 1997 In vivo studies with antisense oligonuletoides Trends Pharmacol Sci 18 12 18 9114724 10.1016/S0165-6147(96)01002-4 1:CAS:528:DyaK2sXht1Glsr4%3D (Pubitemid 27072873)
16. S Kawakami Y Higuchi M Hashida 2008 Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide J Pharm Sci 97 726 745 17823947 10.1002/jps.21024 1:CAS:528:DC%2BD1cXhvFaks7w%3D (Pubitemid 351293877)
17. N Matsuda Y Hattori Y Takahashi J Nishihira S Jesmin M Kobayashi S Gando 2004 Therapeutic effect of in vivo transfection of transcription factor decoy to NF-κB on septic lung in mice Am J Physiol Lung Cell Mol Physiol 287 L1248 L1255 15298852 10.1152/ajplung.00164.2004 1:CAS:528:DC%2BD2cXhtFShsLfL (Pubitemid 39507204)
18. N Matsuda Y Hattori S Jesmin S Gando 2004 Nuclear factor-κB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis Mol Pharmacol 67 1018 1025 15576632 10.1124/mol.104. 005926 (Pubitemid 40410404)
19. Y Higuchi S Kawakami M Oka F Yamashita M Hashida 2006 Suppression of TNFalpha production in LPS induced liver failure in mice after intravenous injection of cationic liposomes/NFkappaB decoy complex Pharmazie 61 144 147 16526563 1:CAS:528:DC%2BD28XhvVGqt7s%3D (Pubitemid 43293898)
20. G De Rosa MC Maiuri F Ungaro D De Stefano F Quaglia MI La Rotonda R Carnuccio 2005 Enhanced intracellular uptake and inhibition of NF-kappaB activation by decoy oligonucleotide released from PLGA microspheres J Gene Med 7 771 781 15702489 10.1002/jgm.724 (Pubitemid 40872863)
21. Y Hattori M Sakaguchi Y Maitani 2006 Folate-linked lipid-based nanoparticles deliver a NFkappaB decoy into activated murine macrophage-like RAW264.7 cells Biol Pharm Bull 29 1516 1520 16819203 10.1248/bpb.29.1516 1:CAS:528:DC%2BD28XovFKqtLk%3D
22. Y Sugao K Watanabe Y Higuchi R Kurihara S Kawakami M Hashida Y Katayama T Niidome 2009 NFkappaB decoy delivery using dendritic poly(l-lysine) for treatment of endotoxin-induced hepatitis in mice Bioorg Med Chem 17 4990 4995 19539484 10.1016/j.bmc.2009.05.081 1:CAS:528:DC%2BD1MXosVyrtro%3D
23. S Kawakami A Sato M Nishikawa F Yamashita M Hashida 2000 Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes Gene Ther 7 292 299 10694809 10.1038/sj.gt.3301089 1:CAS:528:DC%2BD3cXhtlams70%3D (Pubitemid 30119732)
24. Y Higuchi S Kawakami M Oka Y Yabe F Yamashita M Hashida 2006 Intravenous administration of mannosylated cationic liposome/NFkappaB decoy complexes effectively prevent LPS-induced cytokine production in a murine liver failure model FEBS Lett 580 3706 3714 16765948 10.1016/j.febslet.2006.05.059 1:CAS:528:DC%2BD28XmtVOmtb8%3D (Pubitemid 43902808)
25. F Sakurai R Inoue Y Nishino A Okuda O Matsumoto T Taga F Yamashita Y Takakura M Hashida 2000 Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression J Control Release 66 255 269 10742585 10.1016/S0168-3659(99)00280-1 1:CAS:528:DC%2BD3cXhvF2ksro%3D (Pubitemid 30160862)
26. Y Higuchi M Oka S Kawakami M Hashida 2008 Mannosylated semiconductor quantum dots for the labeling of macrophages J Control Release 125 131 136 18045722 10.1016/j.jconrel.2007.10.007 1:CAS:528:DC%2BD1cXhtFWrsA%3D%3D (Pubitemid 350299603)
27. S Oyagi M Hirose M Kojima M Okuyama M Kawase T Nakamura H Ohgushi K Yagi 2006 Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats J Hepatol 44 742 748 16469408 10.1016/j.jhep.2005. 10.026 1:CAS:528:DC%2BD28XisFyqtL0%3D
28. H Sands LJ Gorey-Feret AJ Cocuzza FW Hobbs D Chidester GL Trainor 1994 Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate Mol Pharmacol 45 932 943 8190109 1:CAS:528:DyaK2cXkslaqu7c%3D (Pubitemid 24155784)
29. MA Behlke 2008 Chemical modification of siRNAs for in vivo use Oligonucleotides 18 305 319 19025401 10.1089/oli.2008.0164 1:CAS:528: DC%2BD1cXhsVGhu77N (Pubitemid 352791344)
30. Y Higuchi S Kawakami M Hashida 2010 Strategies for in vivo delivery of siRNAs: recent progress BioDrugs 24 195 205 20462284 10.2165/11534450-000000000- 00000 1:CAS:528:DC%2BC3cXos1Sisb0%3D
31. N Tomita H Azuma Y Kaneda T Ogihara R Morishita 2004 Application of decoy oligodeoxynucleotides-based approach to renal diseases Curr Drug Targets 5 717 733 15578952 10.2174/1389450043345146 1:CAS:528:DC%2BD2cXhtVKlsrzI (Pubitemid 39600010)
32. Zhao Q, Temsamani J, Iadarola PL, Jiang Z, Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Effect of different chemically modified oligodeoxynucleotides on immune stimulation.
33. H Liang Y Nishioka CF Reich DS Pisetsky PE Lipsky 1996 Activation of human B cells by phosphorothioate oligodeoxynucleotides J Clin Invest 98 1119 1129 8787674 10.1172/JCI118894 1:CAS:528:DyaK28XlsFaksbc%3D (Pubitemid 26299924)
34. Wijagkanalan W, Kawakami S, Higuchi Y, Yamashita F, Hashida M. Intratracheally instilled mannosylated cationic liposome/NFkappaB decoy complexes for effective prevention of LPS-induced lung inflammation. In press.
35. H Shimizu H Nakagami I Tsukamoto S Morita Y Kunugiza T Tomita H Yoshikawa Y Kaneda T Ogihara R Morishita 2006 NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts Gene Ther 13 933 941 16511526 10.1038/sj.gt.3302711 1:CAS:528:DC%2BD28Xlt1Ois7s%3D (Pubitemid 43827335)